Physiological Effects of ANGPTL3 Variants in Humans
University of Pennsylvania · with National Heart, Lung, and Blood Institute (NHLBI) · NCT04234724
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 50
- US sites recruiting
- 1
- Study start
- December 1, 2020
- Record last updated
- September 10, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
To evaluate the role of ANGPTL3, on lipid metabolism. To explore the role of this protein on glucose metabolism.
Being studied: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Conditions: Hypocholesterolemia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subjects aged 18 or older meeting at least one of the following criteria
- Carrying genetic variants in the gene encoding for ANGPTL3,
- Unaffected controls matched for age, race, gender,
- Willing to follow study procedures
- Able to provide inform consent
Exclusion Criteria
- Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data
- Taking any medication that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data
- Women that are pregnant or nursing
- History of liver disease or abnormal liver function tests (>2x upper limit of normal)
- History of kidney disease or chronic renal insufficiency (eGFR \<60 mL/min/1.73 m2)
- Uncontrolled hypertension (>160/100 mmHg)
- Uncontrolled diabetes
- Anemia (hemoglobin \<11.0 mg/dL) History of a non-skin malignancy within the previous 5 years Major surgery within the past 3 months
- History of any organ transplant
- History of alcohol or drug abuse
- Participation in clinical trials assessing the efficacy and safety of drugs affecting lipid metabolism within the past 6 weeks (or longer depending on the known half-life of the drug) that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data
- Inability to comply to study procedures
Recruiting US locations
University of Pennsylvania
Philadelphia, PA 19104
Site contact: Lauren Vincent, MRA · 215-615-5448
Study contacts (from the official record)
- Marina Cuchel, MD, PhD · 215-662-7188 · mcuchel@pennmedicine.upenn.edu
Similar studies in Pennsylvania
All heart & blood pressure studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Pittsburgh, PA + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersEarly Phase 1
PET Image in PAH Patients
Stephen Y. Chan
- Location
- Pittsburgh, PA
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
BoxX-NoAF Clinical Trial
AtriCure, Inc.
- Location
- Pittsburgh, PA + 30 other US sites
- Eligibility basics
- Ages 65+